These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31269546)

  • 21. [Genetic basis for skeletal disease. CNP therapy for achondroplasia].
    Yasoda A; Nakao K
    Clin Calcium; 2010 Aug; 20(8):1212-8. PubMed ID: 20675932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial.
    Savarirayan R; Hoernschemeyer DG; Ljungberg M; Zarate YA; Bacino CA; Bober MB; Legare JM; Högler W; Quattrin T; Abuzzahab MJ; Hofman PL; White KK; Ma NS; Schnabel D; Sousa SB; Mao M; Smith A; Chakraborty M; Giwa A; Winding B; Volck B; Shu AD; McDonnell C
    EClinicalMedicine; 2023 Nov; 65():102258. PubMed ID: 37823031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New treatments for achondroplasia may be efficacious in other forms of short stature].
    Nilsson O
    Lakartidningen; 2021 Feb; 118():. PubMed ID: 33647161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
    Wendt DJ; Dvorak-Ewell M; Bullens S; Lorget F; Bell SM; Peng J; Castillo S; Aoyagi-Scharber M; O'Neill CA; Krejci P; Wilcox WR; Rimoin DL; Bunting S
    J Pharmacol Exp Ther; 2015 Apr; 353(1):132-49. PubMed ID: 25650377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype.
    Tanaka H; Kubo T; Yamate T; Ono T; Kanzaki S; Seino Y
    Eur J Endocrinol; 1998 Mar; 138(3):275-80. PubMed ID: 9539301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth and growth hormone therapy in children with achondroplasia: a two-year experience.
    Stamoyannou L; Karachaliou F; Neou P; Papataxiarchou K; Pistevos G; Bartsocas CS
    Am J Med Genet; 1997 Oct; 72(1):71-6. PubMed ID: 9295079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes and medical management of achondroplasia in Japanese children: A retrospective medical record review of clinical data.
    Saitou H; Kitaoka T; Kubota T; Kanno J; Mochizuki H; Michigami T; Hasegawa K; Fujiwara I; Hamajima T; Harada D; Seki Y; Nagasaki K; Dateki S; Namba N; Tokuoka H; Pimenta JM; Cohen S; Ozono K
    Am J Med Genet A; 2024 Aug; 194(8):e63612. PubMed ID: 38554024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulatory CNP Rescues Craniofacial Hypoplasia in Achondroplasia.
    Yamanaka S; Nakao K; Koyama N; Isobe Y; Ueda Y; Kanai Y; Kondo E; Fujii T; Miura M; Yasoda A; Nakao K; Bessho K
    J Dent Res; 2017 Dec; 96(13):1526-1534. PubMed ID: 28644737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis.
    Miccoli M; Bertelloni S; Massart F
    Horm Res Paediatr; 2016; 86(1):27-34. PubMed ID: 27355624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.
    Wrobel W; Pach E; Ben-Skowronek I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promising horizons in achondroplasia along with the development of new drugs.
    Ozono K; Kubota T; Michigami T
    Endocr J; 2024 Jul; 71(7):643-650. PubMed ID: 38569854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth-promoting effect of human growth hormone on patients with achondroplasia.
    Okabe T; Nishikawa K; Miyamori C; Sato T
    Acta Paediatr Jpn; 1991 Jun; 33(3):357-62. PubMed ID: 1785332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of achondroplasia with growth hormone: six years of experience.
    Ramaswami U; Rumsby G; Spoudeas HA; Hindmarsh PC; Brook CG
    Pediatr Res; 1999 Oct; 46(4):435-9. PubMed ID: 10509364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and evaluation of novel natriuretic peptide derivatives with improved pharmacokinetic and pharmacodynamic properties.
    Morozumi N; Sato S; Yoshida S; Harada Y; Furuya M; Minamitake Y; Kangawa K
    Peptides; 2017 Nov; 97():16-21. PubMed ID: 28899838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consensus Guidelines for the Use of Vosoritide in Children with Achondroplasia in Australia.
    Tofts L; Ireland P; Tate T; Raj S; Carroll T; Munns CF; Knipe S; Langdon K; McGregor L; McKenzie F; Zankl A; Savarirayan R
    Children (Basel); 2024 Jun; 11(7):. PubMed ID: 39062238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone therapy in achondroplasia.
    Seino Y; Yamanaka Y; Shinohara M; Ikegami S; Koike M; Miyazawa M; Inoue M; Moriwake T; Tanaka H
    Horm Res; 2000; 53 Suppl 3():53-6. PubMed ID: 10971105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Final adult height in long-term growth hormone-treated achondroplasia patients.
    Harada D; Namba N; Hanioka Y; Ueyama K; Sakamoto N; Nakano Y; Izui M; Nagamatsu Y; Kashiwagi H; Yamamuro M; Ishiura Y; Ogitani A; Seino Y
    Eur J Pediatr; 2017 Jul; 176(7):873-879. PubMed ID: 28501952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone therapy in achondroplasia.
    Nishi Y; Kajiyama M; Miyagawa S; Fujiwara M; Hamamoto K
    Acta Endocrinol (Copenh); 1993 May; 128(5):394-6. PubMed ID: 8317186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
    Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
    N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study.
    Savarirayan R; Irving M; Harmatz P; Delgado B; Wilcox WR; Philips J; Owen N; Bacino CA; Tofts L; Charrow J; Polgreen LE; Hoover-Fong J; Arundel P; Ginebreda I; Saal HM; Basel D; Font RU; Ozono K; Bober MB; Cormier-Daire V; Le Quan Sang KH; Baujat G; Alanay Y; Rutsch F; Hoernschemeyer D; Mohnike K; Mochizuki H; Tajima A; Kotani Y; Weaver DD; White KK; Army C; Larrimore K; Gregg K; Jeha G; Milligan C; Fisheleva E; Huntsman-Labed A; Day J
    Genet Med; 2022 Dec; 24(12):2444-2452. PubMed ID: 36107167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.